| Autor: |
Spindler, Karen-Lise Garm, Lindebjerg, Jan, Lahn, Michael, Kjaer-Frifeldt, Sanne, Jakobsen, Anders |
| Předmět: |
|
| Zdroj: |
International Journal of Colorectal Disease; Jun2009, Vol. 24 Issue 6, p641-645, 5p, 1 Color Photograph, 2 Charts, 1 Graph |
| Abstrakt: |
Current development of targeted agents for the treatment of colorectal cancer include the clinical evaluation of kinase inhibitors, such as enzastaurin, a serine/threonine kinase inhibitor designed to suppress signaling through Protein Kinase C (PKC) and AKT pathways. Little is known about the expression of PKC-β in colorectal cancer or the prognostic value in colorectal cancer, which was the focus of the present study. PKC-βII protein expression was examined in 99 primary colorectal adenocarcinomas and 33 corresponding regional lymph node metastases by immunohistochemistry (IHC). The PKC-βII immunoreactivity was mutually compared and correlated with survival information of all examined patients. Immunohistochemical expression of PKC-βII was detected in 18/99 carcinomas (18.2%). There was no correlation between PKC-βII staining and traditional clinicopathological parameters. However the median survival was 2.2 years in PKC-βII expressing tumors compared to 5.4 in PKC-βII negative tumors ( p = 0.25), with a trend for association to poor prognosis. We here describe for the first time the immunohistochemical detection of PKC-βII in patients with colorectal cancer and show a trend associating with poor survival. The role of PKC-βII staining in colorectal tumors deserves further evaluation. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink